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Background. The Expanded Program on Immunization (EPI) is the most cost-effective measures to control vaccine-preventable
diseases. Currently, the EPI schedule is similar for HIV-infected children; the introduction of antiretroviral therapy (ART) should
considerably prolong their life expectancy. Methods and Principal Findings. To evaluate the persistence of antibodies to the
EPI vaccines in HIV-infected and HIV-exposed uninfected children who previously received these vaccines in routine clinical
practice, we conducted a cross-sectional study of children, aged 18 to 36 months, born to HIV-infected mothers and living in
Central Africa. We tested blood samples for antibodies to the combined diphtheria, tetanus, and whole-cell pertussis (DTwP),
the measles and the oral polio (OPV) vaccines. We enrolled 51 HIV-infected children of whom 33 were receiving ART, and 78
HIV-uninfected children born to HIV-infected women. A lower proportion of HIV-infected children than uninfected children had
antibodies to the tested antigens with the exception of the OPV types 1 and 2. This difference was substantial for the measles
vaccine (20% of the HIV-infected children and 56% of the HIV-exposed uninfected children, p,0.0001). We observed a high risk
of low antibody levels for all EPI vaccines, except OPV types 1 and 2, in HIV-infected children with severe immunodeficiency
(CD4
+ T cells ,25%). Conclusions and Significance. Children were examined at a time when their antibody concentrations to
EPI vaccines would have still not undergone significant decay. However, we showed that the antibody concentrations were
lowered in HIV-infected children. Moreover, antibody concentration after a single dose of the measles vaccine was
substantially lower than expected, particularly low in HIV-infected children with low CD4
+ T cell counts. This study supports the
need for a second dose of the measles vaccine and for a booster dose of the DTwP and OPV vaccines to maintain the antibody
concentrations in HIV-infected and HIV-exposed uninfected children.
Citation: Tejiokem MC, Gouandjika I, Be ´niguel L, Zanga Marie-Claire E, Tene G, et al (2007) HIV-Infected Children Living in Central Africa Have Low
Persistence of Antibodies to Vaccines Used in the Expanded Program on Immunization. PLoS ONE 2(12): e1260. doi:10.1371/journal.pone.0001260
INTRODUCTION
Pediatric HIV infection is a major public health threat. Two thirds
of the 700,000 [630,000 to 820,000] children less than 15 years
old newly infected with HIV in 2005 were living in sub-Saharan
Africa [1]. Mother to child transmission of HIV is still a major
route of infection for children. This is related mainly to insufficient
access to prevention methods, HIV screening and antiretroviral
treatment (ART) in developing countries. Without appropriate
ART, HIV-infected children experience progressive immune
depression and become susceptible to infectious diseases, some of
which could be prevented by immunization.
The World Health Organization (WHO) recommendations for
immunization of HIV-infected children differ slightly from the
general guidelines for HIV-uninfected children [2]. The use of
vaccines in HIV-infected and HIV-exposed uninfected children
raises questions about the capacity of those children to mount and
maintain efficacious antibody levels. Several clinical trials in HIV-
infected children report low antibody levels to various vaccines
[reviewed in 3, 4].
In this study, we evaluated the persistence of antibody levels in
HIV-infected and HIV-exposed uninfected children born to HIV-
infected mothers, living in Central Africa and who previously
received EPI vaccines in routine clinical practice. In addition, we
assessed the influence of host and viral related factors (nutritional,
clinical and biological) on the association between HIV infection
and the absence of antibody to EPI vaccines.
METHODS
Participants
We conducted a cross-sectional study in 4 pediatric care centers (3
in Cameroon and 1 in the Central African Republic (CAR)).
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Children were eligible if: (i) they were between 18 and 36 months
of age; (ii) they were born (not prematurely, i.e. $ 37 weeks) to an
HIV-infected mother who was diagnosed in the context of the
mother to child transmission prevention program; and (iii) they
had received at least a primary vaccine series of three doses of the
combined diphtheria, tetanus, and whole-cell pertussis (DTwP)
vaccine, the total oral polio (TOPV) before one year of age, and
one dose of the measles vaccine (documented on an immunization
card). The HIV-1 status has been already confirmed by serology in
all included children between 15 and 18 months of age. Children
were not included in the study if (i) their clinical status was severely
impaired (including advanced or severe HIV-associated symptoms)
or (ii) they were breastfed six months before the enrolment period
to avoid recent HIV infection through breastfeeding.
The EPI schedule in both countries included BCG vaccination
and one dose of TOPV (dose 0) given at birth; a primary
vaccination with three doses of the DTwP combined vaccine and
TOPV given at 6, 10, and 14 weeks; and recommended booster
doses of the DTwP combined vaccine and TOPV given at
18 months of age. The measles vaccine was scheduled to be given
at nine months of age and a second dose was recommended at 12
to 15 months of age.
Ethics
All parents or legal guardians gave written informed consent. The
study was approved by National Ethics Committees in Cameroon
and in CAR. The study was conducted in accordance with the
Declaration of Helsinki.
Laboratory techniques
Blood samples were collected and processed at the Centre Pasteur
in Yaounde ´ (Cameroon) and at the Institut Pasteur in Bangui
(CAR). Complete blood count, proteinemia and tests for HIV-1-
infected children including assessment of HIV-1 viral load and
lymphocyte subpopulation counts were done. Thick blood smears
were also performed for malaria diagnostics. In Cameroon, the
plasma HIV-1 RNA viral load (VL) was quantified by a
commercial assay (VersantH bDNA HIV kit version 3.0, Bayer
Diagnostics, Emeryville, CA, USA) according to the manufactur-
er’s instructions. The threshold for quantification was 50 HIV-1
RNA copies/ml. In Bangui, values for the plasma HIV-1 RNA
were determined by real-time TaqMan RT-PCR with the
protocol established by the Working Group for Viral Quantifica-
tion of the ANRS [5]. The limit for quantification was 400 HIV-1
RNA copies/ml. The CD4
+ T cells were counted with a
fluorescence activated cell sorter (FacScan) flow cytometer (Becton
Dickinson Biosciences, San Jose, CA, USA).
The antibody concentrations or titers to measles, diphtheria,
tetanus, and polio types 1, 2 and 3 were analyzed at the laboratory
sites. Serological testing for pertussis was performed by the French
National Reference Center for Bordetella. All the samples were tested
in duplicates, and results were expressed as the mean values for the
two determinations. The antibody level was considered adequate if
the antibody concentration or titer was above the cut-off value
defined by the manufacturers or by WHO recommendations.
Antibodies to measles were initially measured with a commer-
cial ELISA kit (Enzygnost Anti-measles virus/IgG, Dade Behring,
Germany) in which plates were coated with inactivated measles
virus [6]. The assay was calibrated using an international reference
reagent for the measles vaccine (National Institute for Biological
Standards and Control (NIBSC) #92/648, Hertfordshire, UK).
The results were classified as negative (DOD ,100 mUI/ml) or
equivocal (100 # DOD # 335 mUI/ml). Quantitative values were
calculated for positive samples (DOD.335 mUI/ml). Because the
percentage of positive samples was low in both groups (16% and
62.3% of in HIV-infected and uninfected children, respectively)
with this initial technique, all samples were re-tested for antibodies
to measles using an IgG capture enzyme immunoassay (Measles
IgG capture EIA, Microimmune Ldt, Brentford, UK) [7]. This
qualitative assay was done by the Laboratory of Virology at the
University Hospital of Caen (France), the French Associated
Reference Center for Measles. Briefly, plates were coated with
anti-human IgG and a recombinant measles nucleoprotein antigen
was used to detect specific IgG against measles. Sera were
identified as IgG positive if the OD was at least 1.25 times higher
than the mean OD of three negative control wells.
Antibodies to diphtheria and tetanus toxoids were measured
using commercial ELISA kits (Diphteria ELISA IgG Testkit and
Tetanus ELISA IgG Testkit, Genzyme Virotech, Russelsheim,
Germany). Sera with antibody concentrations of, at least,
100 mIU/ml were considered positive. For the wP vaccine,
agglutinins (AGG), i.e. antibodies that agglutinate bacteria mostly
directed against fimbrial antigens, were measured. These AGG
were detected by the classical micro-agglutination test [8].
Adequate results were defined as values equal to or superior to
the value for the first dilution tested (1/20 dilution).
Neutralizing antibody titers against each of the three poliovirus
types were measured using a micro-neutralizing assay, based on
the WHO recommended procedure [9]. The potency of the in-
house reference serum (identical for both sites) was assayed in
parallel with the second International Reference Reagent for live
attenuated poliovirus (NIBSC #66/202) so that the results could
be converted to International Units (IU). Two-fold dilutions of sera
ranging from 1/8 to 1/1024 were incubated for three hours at
36uC in triplicate with 100 median TCID50 doses of the
corresponding Sabin-type poliovirus. HEp-2 cells were added
and plates were scored after five days. The neutralizing antibody
titer was the end point dilution of sera that protected 50% of the
cell culture. Detectable antibody at a dilution of 1:8 was
considered positive for that poliovirus serotype (equivalent to 0.6
IU for poliovirus 1, 1.1 IU for poliovirus 2 and 0.3 IU for
poliovirus 3). The geometric mean concentration (GMC) for each
poliovirus serotype was calculated as IU for all samples.
Statistical methods
The chi-square or Fisher’s exact test was used as appropriate to
compare categorical variables of HIV-infected and uninfected
children. The student’s t-test was used to compare continuous
variables if the data adhered to normality assumptions; otherwise
the Mann-Whitney test was used. The results for antibodies to the
DTwP vaccine, the measles vaccine and the TOPV were reported
as the GMC or GM titers (GMT) with the 95% confidence
intervals (CI) for each group.
Univariate and multivariate logistic regression models were used
to assess the effect of covariates on the odds ratios (OR) of a low
antibody concentration to vaccine (only the serotype 3 for the
OPV). Composite categorical variables were created to evaluate
the effect of HIV infection: i) HIV status combined with the
percentage of CD4
+ T cells (HIV-exposed uninfected, HIV
infected and $25% CD4
+ T cells, HIV infected and ,25%
CD4
+ T cells) [10]; ii) HIV status combined with HIV VL (HIV-
exposed uninfected, HIV infected and VL ,10,000 copies/ml,
HIV infected and VL $10,000 copies/ml) [11]; and iii) HIV
status combined with duration of ART (HIV-exposed uninfected,
HIV infected and $6 months ART, HIV infected and
,6 months of ART or no ART). Six months was chosen as a
EPI Vaccine in HIV Children
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a second line of ART in resource–constrained countries. The
perinatally HIV-exposed uninfected children constituted the
reference group in this study. STATA version 8.0 (Stata Corp,
College Station, TX, USA) was used for all statistical analyses,
with a significance level of 5%.
RESULTS
Study population
The first two criteria for eligibility were met by 177 children (54
HIV-infected and 123 HIV-exposed uninfected), but the third
criteria (EPI schedule) was not fulfilled in three HIV-infected and
45 HIV-exposed uninfected children (44 from CAR). Thus, 129
children were included in the study: 51 perinatally HIV-infected
(16 in the CAR and 35 in Cameroon) and 78 HIV-exposed
uninfected (44 in the CAR and 34 in Cameroon). The mean age of
children enrolled was 24.6 months (90% range; 18.1 to 35.6). Sex
ratio, duration of breastfeeding, weight, MUAC [9], number of
vaccine doses, and the frequency of positive blood smears for
malaria did not statistically differ between the two groups. The
median time interval between the collection of blood for antibody
determination and the last vaccination was 17.3 months (90%
range; 3.9 to 31.3 months) for the DTwP vaccine and 12.8 months
(90% range; 3.3 to 26.1 months) for the measles vaccine.
According to the WHO pediatric clinical staging system [12], 36
(70%) of the HIV-infected children were classified as stage 1 and
15 (29.9%) at stage 2. Almost two thirds of them (33/51) were
receiving ART at the time of inclusion in the study (six in CAR
and 27 in Cameroon); the duration of treatment was at least six
months for 61% (20/33) of the children receiving ART. The mean
age of children starting ART was 18.1 months (90% range: 7.3–
34.2 months), indicating that the majority of the children began
ART several months after they received the first series of the EPI
vaccines. The most frequent ART combinations were
AZT+3TC+NVP (n=22) and D4T+3TC+NVP (n=8). In HIV-
infected children, 61% (31/51) had a plasma VL below 10,000
copies per ml (6 in the CAR and 25 in Cameroon). For 51 HIV-
infected children, the distribution according to the percentages of
CD4
+ T cells was as follows: ,15% (n=15), 15–24% (n=16) and
$ 25% (n=20).
HIV-infected children have low levels of antibodies
to EPI vaccines
We observed that the proportion of HIV-infected children with
adequate antibody levels to all the tested vaccine antigens was
lower than that of HIV-exposed uninfected children (Table 1).
The difference was statistically significant for all tested antigens
with the exception of poliovirus types 1 and 2. The GMCs were
lower in the HIV-infected group than in the HIV-exposed
uninfected group for all tested vaccines with the exception of the
measles vaccine. These differences were statistically significant for
tetanus and poliovirus types 1 to 3. Few children received a
Table 1. Proportions of adequate antibody concentrations or titers to the EPI vaccines and geometric mean concentrations or titers
for antibodies against measles, DTwP and TOPV antigens, according to the HIV status of the children.
..................................................................................................................................................
Vaccine antigens HIV-infected children HIV-exposed uninfected children P1* P2
{
Number of doses N
Adequate
responses n (%) GMC
{ [95% CI] N
Adequate
responses n (%) GMC
{ [95% CI]
Measles
Enzygnost Total 50 8 (16.0) 1091.5 [576.1–2067.8] 77 48 (62.3) 943.2 [782.7–1136.6] ,10
24 0.56
1 dose 46 7 (15.2) 72 45 (62.5) ,10
24
2 doses 4 1 (25.0) 5 3 (60.0) 0.36
Microimmune Total 49 10 (20.4) 77 43 (55.8) ,10
24
1 dose 45 9 (20.0) 72 39 (54.2) ,10
24
2 doses 4 1 (25.0) 5 4 (80.0) 0.21
Diphtheria Total 51 27 (52.9) 245 [166–361] 78 62 (79.5) 312 [246–396] 0.001 0.13
3 doses 44 22 (50.0) 66 51 (77.3) 0.003
4 doses 7 5 (71.4) 12 11 (91.7) 0.29
Tetanus Total 51 43 (84.3) 289 [228–367] 78 76 (97.4) 491 [396–609] 0.01 0.001
3 doses 44 36 (81.8) 66 64 (97.0) 0.01
4 doses 7 7 (100.0) 12 12 (100.0)
Pertussis Total 50 15 (30.0) 52.8 [41.4–67.3] 78 43 (55.1) 62.8 [52.2–75.6] 0.005 0.28
3 doses 43 10 (23.3) 66 34 (51.5) 0.003
4 doses 7 5 (71.4) 12 9 (75.0) 0.63
TOPV $4 doses
Serotype 1 51 48 (94.1) 6.1 [4.5–8.3] 78 78 (100.0) 16.1 [12.1–21.5] 0.06 ,10
25
Serotype 2 51 48 (94.1) 13.2 [ 8.9–19.3] 78 77 (98.7) 42.5 [32.5–58] 0.17 ,10
25
Serotype 3 51 36 (70.6) 2.3 [1.3–3.9] 78 75 (96.2) 4.5 [3.3–6.1] ,10
24 0.02
*P1: P value for the comparison of the proportion of adequate antibody concentrations or titers between HIV-infected and HIV-exposed uninfected children (Chi square
test or Fisher exact test, as appropriate)
{P2: P value for the comparison of the GMC between HIV-infected and HIV-exposed uninfected children (Mann-Whitney test)
{GMC=geometric mean concentration and CI=confidence interval, expressed in mUI/ml, except for poliovirus (UI/ml) and pertussis (GMT).
doi:10.1371/journal.pone.0001260.t001
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measles vaccine (7%). Only 20% (three HIV-infected and 21 HIV-
exposed uninfected) of these children had the expected antibody
levels against all the tested vaccines, 71% (37 HIV-infected and 55
HIV-exposed uninfected) had low antibody levels to one or more
vaccine antigens, and 9% (9 HIV-infected and 1 HIV-exposed
uninfected) did not develop or maintain the expected antibody
level to the vaccine antigens. Moreover, the proportion of children
with low antibody levels to EPI vaccines differed according to the
degree of immunodeficiency, except for the tetanus and the
poliovirus type 3 vaccines (Table 2). Children with CD4
+ T-cell
counts lower than 25% had significantly low levels of antibodies,
particularly to the live attenuated measles vaccine. A short
duration of ART or no ART was significantly associated with a
low measles antibody concentration (tested by EIA) as shown in
the Table 3. Severe immunodeficiency (,25% CD4
+ T cells, HIV
VL $10,000 copies) was also associated with a low antibody
concentration. Only the covariates linked to HIV status (ART, %
CD4
+ T cells, HIV VL, macrocytosis, protidemia) were statistically
significant. More children with low measles antibody concentra-
tion than those with adequate antibody concentrations were
breastfed; however, the difference was weakly significant.
Multivariate logistic regression models were performed for each
EPI vaccine. Only the HIV status-CD4
+ T-cell percentage was
considered in these analysis, due to the high agreement between
the composite categorical variables (HIV status-CD4
+ T-cell
percentage and HIV status-VL, k=0.71 ; HIV status-CD4
+ T-
cell percentage and HIV status-ART, k=0.75 ; HIV status-VL
and HIV status-ART, k=0.71). For each EPI vaccine, HIV-
infected children with severe immunodeficiency (CD4
+ T-cell
percentage ,25%) had a significantly higher risk than HIV-
exposed uninfected children of having low antibody levels
(Table 4). For the poliovirus type 3 vaccine, HIV-infection,
whatever the degree of immunodeficiency, was significantly
associated with a low antibody titers.
DISCUSSION
Soon, the introduction of ART for infants and children living in
resource-constrained settings should considerably prolong their life
expectancy and reduce HIV disease progression. The question of
the long-lasting antibody persistence to EPI vaccines in this
population should now be addressed. In this study, we evaluated
the persistence of antibody levels following routine EPI vaccine
administration in perinatally HIV-infected and HIV-exposed
uninfected children in Central Africa. We found that HIV-
infected children had significantly lower levels of antibodies to the
EPI vaccines than HIV-exposed uninfected children. On one
hand, the proportion of HIV-infected children with expected
antibody concentrations to measles was substantially low; although
HIV-infected responders had GMC similar to the HIV-exposed
uninfected children. On the other hand, although similar
proportions of HIV-infected and HIV-exposed uninfected chil-
dren were found adequate to the poliovirus types 1 and 2 vaccines,
the antibody GMT were lower in HIV-infected children.
In this study, half of the children (44/88) in CAR could not be
included because they did not meet the criteria about the EPI
vaccine schedule showing how much a successful EPI could be
difficult to implement and to maintain at a national level. Logistics
related to supply, storage and administration of vaccines can lead
to difficulty in applying the EPI recommended schedule. A recent
study in Zambia showed a lower rate of EPI vaccine coverage in
HIV-infected children [13]. Moreover, EPI vaccines are provided
free-of-charge only until 12 months of age and we showed that,
consequently, booster doses were almost never administrated in
routine practice as they must be paid for by the families.
Nevertheless, we observed that the few HIV-infected children
who received four doses of the DTwP vaccine had a better
antibody concentration than those who received only the primary
series of three doses. For the measles vaccine, in sub-Saharan
African countries, the first dose of the measles vaccine is
recommended at 9 months of age to increase the protection of
younger children and a second dose, known to improve the level of
immunization, should be administered. Supplemental immuniza-
tion activities (SIA) have been successful in controlling measles in
southern Africa despite a high HIV prevalence [14,15]; but there
were no SIA and the wild-type measles virus still circulating in the
two countries at the time of our study.
Low responsiveness to the measles vaccine in HIV-infected
children has been reported previously [6,16–18]. Attempts to use a
high-dose Edmonston-Zagreb measles vaccine showed a higher
conversion rate [19]; however, the introduction of high-dose
vaccines was abandoned because of safety risks [20]. Waibale et al.
linked low antibody response to the measles vaccine to nutritional
status (stunting) rather than to HIV infection [21]. We did not
include children with very poor general health status in our study
to avoid collecting blood of children with short life-time
expectancy or with on-going infectious disease, which may explain
why we did not observe this link with the nutritional status. In
routine vaccination practice, we observed a low persistence of
antibody to the measles vaccine in all children; this was
particularly marked in HIV-infected children. However, in terms
of clinical protection, one cannot predict if HIV-infected children
with no antibodies to measles despite immunization remain
susceptible or not to measles infection. A recent study demon-
strated a very high mortality level due to measles epidemics in
unvaccinated children from Niger, Nigeria and Chad with case
fatality rates of 4–10% in children under 5 years old [22], thus
reminding the devastating impact of measles in unvaccinated
populations [23]. In HIV-uninfected children born to HIV-
uninfected mothers, the cellular response to the measles vaccine
appears to be induced even after early immunization (at six
Table 2. Low antibody concentrations or titers to the EPI antigens in relation to the percentage of CD4
+ T cells.
..................................................................................................................................................
HIV status % of CD4
+ T cells Measles Diphtheria Tetanus Pertussis Poliovirus serotype 3
OR* 95% CI
{ P OR 95% CI P OR 95% CI P OR 95% CI P OR 95% CI P
HIV-exposed uninfected (Reference) 1 1 1 1 1
HIV infected $ 25% CD4
+ T-cells 2.3 0.8–6.5 0.10 2.6 0.9–7.6 0.07 6.7 1.0–43.3 0.045 1.5 0.6–4.0 0.42 13,5 3.1–58.8 0.001
HIV infected ,25% CD4
+ T-cells 11.0 3.1–39.3 ,10
25 4.1 1.7–10.1 0.002 7.3 1.3–39.9 0.02 4.9 1.8–13.4 0.002 8.7 2.1–35.5 0.003
*Odds ratio
{Confidence interval
doi:10.1371/journal.pone.0001260.t002
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PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1260Table 3. Association between measles antibody concentration and children’s characteristics.
..................................................................................................................................................
Characteristics Measles antibody OR* 95% CI
{ P
{
Low (N=73) n (%) Adequate (N=53) n (%)
Site of inclusion
Yaounde ´ 40 (59.7) 27 (40.3) 1.2 0.6–2.4 0.67
Bangui 33 (55.9) 26 (44.1) 1
HIV status
Infected 39 (79.6) 10 (20.4) 4.9 2.0–12.0 0.0001
HIV-exposed uninfected 34 (44.2) 43 (55.8) 1
HIV status–Antiviral therapy (ART) 0.0001
Duration ART ,6 months 25 (83.3) 5 (16.7) 6.3 2.0–19.7 0.0003
Duration ART $ 6 months 14 (73.7) 5 (26.3) 3.5 1.1–11.2 0.02
HIV-exposed uninfected 34 (44.2) 43 (55.8) 1
HIV status–CD4
+ T cells 0.0001
,25% CD4
+ T-cells 26 (89.7) 3 (10.3) 11.0 3.1–39.3 ,10
25
$ 25% CD4
+ T-cells 13 (65.0) 7 (35.0) 2.3 0.8–6.5 0.10
HIV-exposed uninfected 34 (44.2) 43 (55.8) 1
HIV status–HIV Viral load 0.0001
Viral load $10,000 copies 17 (85.0) 3 (15.0) 7.2 1.8–28.8 0.001
Viral load ,10,000 copies 22 (75.9) 7 (24.1) 4.0 1.4–10.9 0.004
HIV-exposed uninfected 34 (44.2) 43 (55.8) 1
Sex
Female 43 (56.6) 33 (43.4) 0.9 0.4–1.8 0.70
Male 30 (60.0) 20 (40.0) 1
Age of children at time of inclusion
.23 months
1 40 (62.5) 24 (37.5) 1.5 0.7–2.0 0.29
#23 months 33 (53.2) 29 (46.8) 1
Age at vaccination against measles
.12 months 10 (71.4) 4 (28.6) 1.9 0.6–6.6 0.28
#12 months 63 (56.3) 49 (43.7) 1
Breastfeeding
Yes 48 (64.9) 26 (35.1) 2.0 1.0–4.2 0.06
No 25 (48.1) 27 (51.9) 1
Clinical signs
Yes 18 (72.0) 7 (28.0) 2.2 0.8–5.7 0.11
No 55 (54.5) 46 (45.5) 1
MUAC
|| for age
,-2Z score (malnutrition) 18 (72.0) 7 (28.0) 2.2 0.8–5.7 0.11
$-2Z score 55 (54.5) 46 (45.5) 1
Time since last vaccination
$12 months 43 (64.2) 24 (35.8) 1.7 0.8–3.5 0.13
,12 months 30 (50.8) 29 (49.2) 1
Number of doses received
2 doses 4 (44.4) 5 (55.6) 0.6 0.1–2.2 0.49
1 dose 69 (59.0) 48 (41.0) 1
Macrocytosis
MGV
" $83 fl 22 (78.6) 6 (21.4) 3.3 1.2–9.1 0.01
MGV
" ,83 fl 50 (52.6) 45 (47.4) 1
Protidemia
.85 g/l 17 (77.3) 5 (22.7) 2.8 1.0–8.5 0.05
#85 g/l 55 (54.5) 46 (45.5) 1
*Odds ratio of low measles antibody response
{Confidence interval
{Chi square test, Fisher exact test or chi square test for trend as appropriate
1Median age
||Mid upper arm circumference
"Mean globular volume
doi:10.1371/journal.pone.0001260.t003
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PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1260Table 4. Logistic regression analysis of various characteristics of children in relation to low antibody concentrations or titers to EPI
vaccines (HIV-exposed uninfected children as reference group).
..................................................................................................................................................
Vaccines/Characteristics of children Initial model Final model
OR
{ CI
{ 95% p OR CI 95% p
Measles (N=120)
HIV status–,25% CD4
+ T-cells 6.2 (1.5–29.2) 0.01 10.1 (2.8–36.4) 0.0001
HIV status–$25% CD4
+ T-cells 2.1 (0.6–7.1) 0.21 2.6 (0.9–7.7) 0.08
Breastfeeding 1.3 (0.6–3.4) 0.44
Age at vaccination against measles (.12 months) 1.6 (0.4–6.9) 0.51
Presence of clinical signs 0.8 (0.3–2.8) 0.79
Malnutrition (MUAC ,-2Z scores) 1.2 (0.4–3.8) 0.76
Time since last vaccination (.12 months) 1.3 (0.6–3.2) 0.52
Macrocytosis (MGV .85 fl) 2.2 (0.6–7.1) 0.60
Hyperprotinaemia 1.5 (0.4–5.0) 0.24
Diphtheria (N=126)
HIV status–,25% CD4
+ T-cells 3.4 (1.2–10.0) 0.03 3.8 (1.5–9.5) 0.004
HIV status–$25% CD4
+ T-cells 1.6 (0.5–5.7) 0.44 2.4 (0.8–6.9) 0.12
Inclusion site (Yaounde ´) 2.2 (0.8–5.6) 0.11
Sex (female) 1.7 (0.7–4.1) 0.21
Malnutrition (MUAC ,-2Z scores) 1.4 (0.5–4.4) 0.52
Age (.23 months) 1.1 (0.3–4.2) 0.91
Time since last vaccination ($18 months) 1.7 (0.4–6.7) 0.44 2.3 (1.0–5.1) 0.04
Number of doses received (,4 doses) 2.4 (0.5–11.2) 0.27
Macrocytosis (MGV .85 fl) 1.0 (0.4–3.0) 0.94
Pertussis (N=125)
HIV status–,25% CD4
+ T-cells 2.6 (0.8–9.2) 0.12 3.8 (1.3–11.6) 0.02
HIV status–$25% CD4
+ T-cells 0.9 (0.2–3.0) 0.81 1.3 (0.4–3.7) 0.63
Inclusion site (Yaounde ´) 1.5 (0.6–3.8) 0.35
Sex (female) 1.0 (0.4–2.3) 0.97
Malnutrition (MUAC ,-2Z scores) 1.1 (0.4–3.6) 0.83
Presence of clinical signs 6.1 (1.5–24.7) 0.01 4.8 (1.3–17.6) 0.02
Number of doses received (,4 doses) 6.0 (1.5–23.7) 0.01 6.8 (1.8–25.4) 0.004
Time since last vaccination ($18 months) 1.4 (0.5–4.7) 0.40
Macrocytosis (MGV .85 fl) 1.5 (0.5–4.7) 0.44
Tetanus (N=126)
HIV status–,25% CD4
+ T-cells 6.6 (0.6–55.6) 0.12 6.9 (1.1–42.0) 0.04
HIV status–$25% CD4
+ T-cells 2.5 (0.3–17.4) 0.46 4.3 (0.6–30.9) 0.14
Inclusion site (Yaounde ´) 8.1 (0.6–106.1) 0.10
Sex (female) 8.6 (0.8–86.6) 0.07 8.5 (1.0–75.2) 0.05
Age (.23 months) 12.1 (0.6–257.9) 0.11 8.4 (1.0–72.3) 0.05
Malnutrition (MUAC ,-2Z scores) 4.0 (0.4–34.7) 0.22
Breastfeeding (yes) 0.4 (0.05–2.7) 0.33
Time since last vaccination ($18 months) 0.6 (0.04–8.0) 0.69
Macrocytosis (MGV .85 fl) 0.7 (0.1–4.3) 0.72
Polio serotype 3 (N=123)
HIV status–,25% CD4
+ T-cells 3.8 (0.7–22.6) 0.14 7.2 (1.7–30.2) 0.007
HIV status–$25% CD4
+ T-cells 9.4 (1.6–54.0) 0.01 13.8 (3.1–60.9) 0.001
Inclusion site (Yaounde ´) 0.9 (0.2–3.7) 0.86
Sex (female) 1.1 (0.3–3.7) 0.91
Malnutrition (MUAC ,-2Z scores) 1.3 (0.3–5.2) 0.74
Presence of clinical signs 1.6 (0.4–7.5) 0.52
Time since last vaccination ($18 months) 0.7 (0.2–2.7) 0.64
Macrocytosis (MGV .85 fl) 1.7 (0.5–6.3) 0.41
Hyperprotinaemia 1.4 (0.4–5.3) 0.62
{Adjusted Odds Ratio
{Confidence interval
doi:10.1371/journal.pone.0001260.t004
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PLoS ONE | www.plosone.org 6 December 2007 | Issue 12 | e1260months of age), whereas the antibody response remains low or not
detectable at this age [24,25]. Once established, T-cell memory
against measles is long lasting in HIV-uninfected individuals [26].
However, the CD4
+ T-cell deficiency in HIV-infected children
likely impairs mounting an effective memory against vaccines, and
secondary vaccine failure due to a decline in vaccine-induced
antibody over time has been described [27–29].
The poor antibody levels to EPI vaccines observed in perinatally
HIV-infected children is probably related to major immunological
dysfunction involving both cellular and humoral responses. The
peripartum transmission of HIV correlates with rapid disease
progression and a high mortality rate in HIV-infected infants [30].
In adults, it has been recently shown that acute HIV infection
results in a massive and irreversible depletion of mucosal CD4
+
memory T cells, whereas the regenerative capacity of resting
central memory and naı ¨ve T cells remains largely intact [reviewed
in 31, 32]. Systemic immune activation is impaired after such a
profound depletion of CD4
+ memory T cells in the mucosa,
affecting pathogen-specific adaptive responsiveness. These mech-
anisms have not been studied in HIV-infected children born to
HIV-infected mothers. Children were examined at a time when
their antibody concentrations would have peaked and still not
undergone significant decay, suggesting either a lack of inducing
immediate vaccine response or, at least, a lack of immune capacity
to maintain an adequate antibody level.
We included, as a reference group, perinatally HIV-exposed
uninfected children; this was initially for practical reason because
the HIV status of the mothers and the children were already
determined at the time of the cross-sectional study. We expected
similar antibody concentrations in this reference group and in the
HIV unexposed and uninfected children [33,34]. However, a
recent study demonstrates the influence of the maternal HIV
status on the occurrence of severe pneumonia in young South
African children [35]. Little is known about immune activation
and lymphocyte homeostasis in HIV-uninfected children exposed
to HIV during pregnancy. It was previously shown that cell-
mediated immunity and T-cell maturation are altered in HIV-
uninfected infants born to HIV-infected women [36]. More
recently, immune activation and skewing of post-thymic differen-
tiation were evidenced in healthy adolescents born to HIV-
infected mothers [37]. This might explain, in part, the low
antibody concentrations to the measles vaccine (around 60% of
adequate response) observed in HIV-exposed uninfected children.
We also observed that the persistence of antibody to the TOPV,
particularly to types 1 and 2 was less affected in HIV-infected
children than to the other EPI vaccines, as reported previously
[38,39]. The influence of the degree of immunodeficiency has not
been demonstrated for the TOPV. This may be due to the
administration of multiple TOPV doses during yearly national
poliomyelitis immunization campaigns performed in Cameroon
and in CAR for children under 5 years of age. During these
campaigns, children received two drops of the TOPV whatever
their routine vaccination status. However, although the proportion
of children with antibodies to polioviruses types 1 and 2 were high
in both HIV-infected and HIV-exposed uninfected children, the
antibody titers were clearly lower in HIV-infected children even
after supplemental doses of the TOPV. On the contrary, the
proportion of HIV-infected children with antibodies to poliovirus
type 3 was lower as compared to serotypes 1 and 2, but the titers
were similar in both children groups. Lower antibody titers to
poliovirus type 3 as compared to types 1 and 2 have been reported
previously in HIV-uninfected children [40,41].
We unambiguously observed that the proportion of children
with low antibodies levels to the EPI vaccines was associated with
the severity of HIV-induced immunosuppression. The benefits of
using ART for HIV-infected children [42] and of introducing
ART to infants at an early stage [43,44], in terms of morbidity and
mortality, have been now documented. In young children
receiving ART, we also anticipate the improvement of the
immune response to the EPI vaccines. A prospective study
combining early ART therapy and the administration of an EPI
vaccine schedule completed by a supplemental measles vaccine
dose and reinforcing the schedule by booster doses of DTwP and
TOPV vaccines is needed. Aside the EPI vaccines, responses to H.
influenzae type b conjugate, hepatitis B, pneumococcus and yellow
fever vaccines also deserve further investigation in this population.
Our findings also highlight the urgent need to delineate the
mechanisms of cellular and humoral responses to EPI vaccines in
HIV-infected children.
ACKNOWLEDGMENTS
We thank Nicole Guiso and Sophie Guillot at the Institut Pasteur (Paris,
France) for valuable suggestions concerning the DTwP vaccine and the
TOPV. We also thank Prof. Franc ¸ois Freymuth and his staff (Laboratory of
Virology, University Hospital of Caen, France) for their support with
measles serology, Vale ´rie Marquegnies for data management technical
support, Dr Albert Faye for his contribution on HIV treatment in infants,
Yoann Madec and Dr Arnaud Fontanet for the discussion about statistical
analysis, Vale ´rie Mare ´chal who measured the HIV viral loads at the
Institut Pasteur in Bangui and Dr Carine Ngongueu who helped in the
children follow-up in CAR. We would also like to express our profound
gratitude to the hospital staff members and the parents and their children
who participated in the study at the Chantal Biya Foundation and the
Nkolndongo Catholic Health Center in Yaounde ´, the Laquintinie Hospital
in Douala (Cameroon), and the Bangui Paediatric Center (CAR).
Author Contributions
Conceived and designed the experiments: LB MT IG. Performed the
experiments: AK ME IG LB EN. Analyzed the data: RP LB MT.
Contributed reagents/materials/analysis tools: FT DR CB. Wrote the
paper: FT LB MT. Other: Wrote the first draft of the paper: LB.
Recruitment and follow-up of the children: GT JC IP.
REFERENCES
1. WHO/UNAIDS. Report on the global AIDS epidemic (2006) Available: http://
www.unaids.org/en/HIV_data/2006GlobalReport via the Internet. Accessed
15 Sept 2007.
2. WHO. Immunization service delivery and accelerated disease control. Vaccine
Preventable Diseases. World Health Organization (Last update April 2006).
Available: http://www.who.int/immunization_delivery/vaccines via the Inter-
net. Accessed 15 Sept 2007.
3. Moss WJ, Clements CJ, Halsey NA (2003) Immunization of children at risk of
infection with human immunodeficiency virus. Bull World Health Organ 81:
61–70.
4. Pancharoen C, Ananworanich J, Thisyakorn U (2004) Immunization for persons
infected with human immunodeficiency virus. Curr HIV Res 2: 293–299.
5. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, et al. (2005) Transfer
and evaluation of an automated, low-cost real-time reverse transcription-PCR
test for diagnosis and monitoring of human immunodeficiency virus type 1
infection in a West African resource-limited setting. J Clin Microbiol 43:
2709–2717.
6. Scott S, Cumberland P, Shulman CE, Cousens S, Cohen BJ, et al. (2005)
Neonatal measles immunity in rural Kenya: the influence of HIV and placental
malaria infections on placental transfer of antibodies and levels of antibody in
maternal and cord serum samples. J Infect Dis 191: 1854–1860.
7. Cohen BJ, Parry RP, Doblas D, Samuel D, Warrener L, et al. (2006) Measles
immunity testing: comparison of two measles IgG ELISAs with plaque reduction
neutralisation assay. J Virol Methods 131: 209–212.
EPI Vaccine in HIV Children
PLoS ONE | www.plosone.org 7 December 2007 | Issue 12 | e12608. Relyveld E, Oato NH, Guerin N, Coursaget P, Huet M, et al. (1991)
Determination of circulating antibodies directed to pertussis toxin and of
agglutinogens in children vaccinated with either the whole cell or component
pertussis vaccine in France, Japan and Senegal. Vaccine 9: 843–850.
9. WHO (1997) Neutralisation test for polio antibodies In: Manual for the
virological investigation of poliovirus (Chapter 6). pp 44–49.
10. WHO. Antiretroviral therapy of HIV infection in infants and children in
resource-limited settings: recommendations for a public health approach.
Availabl:e http://www.who.int/hiv/pub/guidelines/WHOpaediatric.pdf via
the Internat. Accessed 15 Sept 2007.
11. Dunn D, HIV Paediatric Prognostic Markers Collaborative Study Group (2003)
Short-term risk of disease progression in HIV-1-infected children receiving no
antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362:
1605–1611.
12. de Onis M, Yip R, Mei Z (1997) The development of MUAC-for-age reference
data recommended by a WHO Expert Committee. Bull World Health Organ
75: 11–18.
13. Setse RW, Cutts F, Monze M, Ryon JJ, Quinn TC, et al. (2006) HIV-1 Infection
as a risk factor for incomplete childhood immunization in Zambia. J Trop
Pediatr 52: 324–328.
14. Helfand RF, Moss WJ, Harpaz R, Scott S, Cutts F (2005) Evaluating the impact
of the HIV pandemic on measles control and elimination. Bull World Health
Organ 83: 329–337.
15. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, et al.
(2007) Has the 2005 measles mortality reduction goal been achieved? A natural
history modelling study. Lancet 369: 191–200.
16. Rudy BJ, Rutstein RM, Pinto-Martin J (1994) Responses to measles
immunization in children infected with human immunodeficiency virus.
J Pediatr 125: 72–74.
17. Arpadi SM, Markowitz LE, Baughman AL, Shah K, Adam H, et al. (1996)
Measles antibody in vaccinated human immunodeficiency virus type 1-infected
children. Pediatrics 97: 653–657.
18. Lindgren-Alves CR, Freire LM, Oliveira RC, Guerra HL, Da-Silva EE, et al.
(2001) Search of antimeasles antibodies in HIV-infected children after basic
immunization. J Pediatr (Rio J) 77: 496–502.
19. Lepage P, Dabis F, Msellati P, Hitimana DG, Stevens AM, et al. (1992) Safety
and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in
children with HIV-1 infection. A cohort study in Kigali, Rwanda. Am J Dis
Child 146: 550–555.
20. Garenne M, Leroy O, Beau JP, Sene I (1991) Child mortality after high-titre
measles vaccines: prospective study in Senegal. Lancet 338: 903–907.
21. Waibale P, Bowlin SJ, Mortimer EA Jr, Whalen C (1999) The effect of human
immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G
levels in children vaccinated against measles in Uganda. Int J Epidemiol 28:
341–346.
22. Grais RF, Dubray C, Gerstl S, Guthmann JP, Djibo A, et al. (2007)
Unacceptably high mortality related to measles epidemics in Niger, Nigeria,
and Chad. PLoS Med 4: e16. Available: http://medicine.plosjournals.org via
the Internet. Accessed 17 Sept 2007.
23. Moss WJ (2007) Measles still has a devastating impact in unvaccinated
populations. PLoS Med 2007 4: e24. Available: http://medicine.plosjournals.
org via the Internet. Accessed 17 Sept 2007.
24. Bautista-Lopez N, Ward BJ, Mills E, McCormick D, Martel N, et al. (2000)
Development and durability of measles antigen-specific lymphoproliferative
response after MMR vaccination. Vaccine 18: 1393–1401.
25. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, et al. (2001) Immune
responses to measles and mumps vaccination of infants at 6, 9, and 12 months.
J Infect Dis 184: 817–826.
26. Naniche D, Garenne M, Rae C, Manchester M, Buchta R, et al. (2004)
Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects.
J Infect Dis 190: 1387–1395.
27. Al-Attar I, Reisman J, Muehlmann M, McIntosh K (1995) Decline of measles
antibody titers after immunization in human immunodeficiency virus-infected
children. Pediatr Infect Dis J 14: 149–151.
28. Brunell PA, Vimal V, Sandu M, Courville TM, Daar E, et al. (1995)
Abnormalities of measles antibody response in human immunodeficiency virus
type 1 (HIV-1) infection. J Acquir Immune Defic Syndr Hum Retrovirol. 10:
540–548.
29. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, et al. (2006) Persistent
humoral immune defect in highly active antiretroviral therapy-treated children
with HIV-1 infection: loss of specific antibodies against attenuated vaccine
strains and natural viral infection. Pediatrics 118: 315–322.
30. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, et al. (2004)
Mortality of infected and uninfected infants born to HIV-infected mothers in
Africa: a pooled analysis. Lancet 364: 1236–1243.
31. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ (2006) Pathogenesis of
HIV infection: what the virus spares is as important as what it destroys. Nat Med
212: 289–295.
32. Brenchley JM, Price DA, Douek DC (2006) HIV disease: fallout from a mucosal
catastrophe? Nat Immunol 7: 235–239.
33. Lepage P, Msellati P, Hitimana DG, Bazubagira A, Van Goethem C, et al.
(1996) Growth of human immunodeficiency type 1-infected and uninfected
children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993. Pediatr
Infect Dis J 15: 479–485.
34. Taha TE, Graham SM, Kumwenda NI, Broadhead RL, Hoover DR, et al.
(2000) Morbidity among human immunodeficiency virus-1-infected and -
uninfected African children. Pediatrics 106: E77.
35. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, et al. (2007) Effect of
age, polymicrobial disease, and maternal HIV status on treatment response and
cause of severe pneumonia in South African children: a prospective descriptive
study. Lancet 369: 1440–1451.
36. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, et al. (2000) T-lymphocyte
maturation abnormalities in uninfected newborns and children with vertical
exposure to HIV. Blood 96: 3866–3871.
37. Vigano A, Saresella M, Schenal M, Erba P, Piacentini L, et al. (2007) Immune
activation and normal levels of endogenous antivirals are seen in healthy
adolescents born of HIV-infected mothers. AIDS 21: 245–248.
38. Barbi M, Biffi MR, Binda S, Clerici-Schoeller M, Ferraris G, et al. (1992)
Immunization in children with HIV seropositivity at birth: antibody response to
polio vaccine and tetanus toxoid. AIDS 6: 1465–1469.
39. Ryder RW, Oxtoby MJ, Mvula M, Batter V, Baende E, et al. (1993) Safety and
immunogenicity of bacille Calmette-Guerin, diphtheria-tetanus-pertussis, and
oral polio vaccines in newborn children in Zaire infected with human
immunodeficiency virus type 1. J Pediatr 122: 697–702.
40. Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, et al. (2000)
Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 343:
767–773.
41. Triki H, Abdallah MV, Ben Aissa R, Bouratbine A, Ben Ali Kacem M, et al.
(1997) Influence of host related factors on the antibody response to trivalent oral
polio vaccine in Tunisian infants. Vaccine 15: 1123–1129.
42. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, et al. (2004)
Highly active antiretroviral therapies among HIV-1-infected children in
Abidjan, Cote d’Ivoire. AIDS 18: 1905–1913.
43. Faye A, Le Chenadec J, Dollfus C, Thuret I, Douard D, et al. (2004) Early versus
deferred antiretroviral multidrug therapy in infants infected with HIV type 1.
Clin Infect Dis 39: 1692–1698.
44. Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, et al. (2006)
Virologic, immunologic, and clinical benefits from early combined antiretroviral
therapy in infants with perinatal HIV-1 infection. AIDS 20: 207–215.
EPI Vaccine in HIV Children
PLoS ONE | www.plosone.org 8 December 2007 | Issue 12 | e1260